Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Orilissa

Roche Basel Switzerland

Roche’s Gazyvaro flunks trial in non-Hodgkin’s lymphoma

Failed to improve progression-free survival when compared with its MabThera/Rituxan therapy

- PMLiVE

Novartis gets FDA panel backing for biosimilar Enbrel

However Amgen claims patent protection for the psoriatic arthritis therapy is valid until 2029

EU flag

European pharma ‘to grow 3.2% per year by 2022’

Forecast predicts AbbVie’s Humira will be knocked off the top spot

- PMLiVE

FDA approves Gilead’s ‘universal’ hep C combination Epclusa

Adds a third Sovaldi-based treatment to the firm’s portfolio

National Institute for Health and Care Excellence NICE logo

NICE backs five new drugs after discounts agreed

Includes Novartis’ previously rejected lung cancer and melanoma therapies Zykadia and Mekinist

- PMLiVE

SMC approves Amgen orphan drug for use in NHS Scotland

Also accepts AbbVie's former orphan drug Duodopa, but rejects Sanofi's Jevtana

- PMLiVE

AbbVie launches chronic skin disease awareness campaign

Online educational resource aims to improve understanding and accelerate diagnosis

- PMLiVE

Trial of AbbVie’s Rova-T disappoints at ASCO

But company says the modest trial data is “a good early sign” for lung cancer drug

EU flag

Imbruvica wins wider European leukaemia licence

AbbVie and J&J’s first-in-class drug now approved to treat all CLL patients in the EU

Biogen Idec building

Biogen and AbbVie bag FDA approval for multiple sclerosis drug

Once-monthly, self-administered Zinbryta ‘significantly’ reduces relapse rate

Novartis building

Novartis says Cosentyx is ‘outpacing competitors’

Claims new psoriasis drug has almost a third of the market share in Germany alone

Allergan logo

Allergan on course to file uterine fibroid drug next year

New drug could be safer and more effective than existing treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links